- Home
- IVVD vs COYA Comparison
IVVD vs COYA Comparison
Compare IVVD & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- COYA
- Stock Information
- Founded
- IVVD 2020
- COYA 2020
- Country
- IVVD United States
- COYA United States
- Employees
- IVVD N/A
- COYA N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- IVVD Health Care
- COYA Health Care
- Exchange
- IVVD Nasdaq
- COYA Nasdaq
- Market Cap
- IVVD 116.8M
- COYA 104.3M
- IPO Year
- IVVD 2021
- COYA 2022
- Fundamental
- Price
- IVVD $0.44
- COYA $5.24
- Analyst Decision
- IVVD Strong Buy
- COYA Strong Buy
- Analyst Count
- IVVD 4
- COYA 4
- Target Price
- IVVD $7.89
- COYA $16.25
- AVG Volume (30 Days)
- IVVD 981.7K
- COYA 78.0K
- Earning Date
- IVVD 11-14-2024
- COYA 11-06-2024
- Dividend Yield
- IVVD N/A
- COYA N/A
- EPS Growth
- IVVD N/A
- COYA N/A
- EPS
- IVVD N/A
- COYA N/A
- Revenue
- IVVD $11,564,000.00
- COYA $9,554,315.00
- Revenue This Year
- IVVD N/A
- COYA N/A
- Revenue Next Year
- IVVD $486.65
- COYA $87.80
- P/E Ratio
- IVVD N/A
- COYA N/A
- Revenue Growth
- IVVD N/A
- COYA N/A
- 52 Week Low
- IVVD $0.40
- COYA $4.75
- 52 Week High
- IVVD $5.20
- COYA $10.69
- Technical
- Relative Strength Index (RSI)
- IVVD 29.58
- COYA 32.54
- Support Level
- IVVD $0.57
- COYA $5.07
- Resistance Level
- IVVD $0.51
- COYA $5.96
- Average True Range (ATR)
- IVVD 0.06
- COYA 0.38
- MACD
- IVVD -0.01
- COYA -0.06
- Stochastic Oscillator
- IVVD 13.30
- COYA 12.45
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.